Samsung Biologics’ KRW2.7T Rights Offering Oversubscribed
Samsung Biologics received bids for 11.9 million new shares against 2.3 million offered. The company previously said the sale would help fund its PolyPeptide acquisition.
(06:05 GMT) *Samsung Biologics: About KRW2.7T Rights Offering Was Oversubscribed Last Week (06:07 GMT) *Samsung Biologics: Received Bids for 11.9M New Shares Against 2.3M Offered (06:08 GMT) *Samsung Biologics Previously Said Share Sale Aimed at Helping Fund PolyPeptide Acquisition (06:26 GMT) Sams…